← All trials
NCT04762199
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2021
- Primary completion
- Dec 27, 2024
- Completion date
- Dec 27, 2024
- First posted
- Feb 21, 2021
- Last posted
- Oct 25, 2021
- Enrollment
- 69
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Emory UniversityLead sponsor
- National Cancer Institute (NCI)Collaborator
- Emory UniversityOverall official - principal investigator
- Emory UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.